| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 52(2); 2020 > Article
Wang, Xiao, Qi, Song, and Yu: Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy



Fractionated radiotherapy as well as concomitant and adjuvant chemotherapy such as temozolomide for postoperative high-grade glioma (HGG) patients improves progression-free survival and overall survival. Multiple factors such as chemotherapy, radiotherapy, tumor grade, residual tumor volume, and genetic modifications might play a role in the formation of cognitive impairment. The risk factors of cognitive impairment in postoperative patients with HGG receiving radiotherapy and chemotherapy remains a concern in this population. The purpose of this study was to identify risk factors for cognitive impairment in patients of postoperative HGG.

Materials and Methods

A total of 229 patients with HGG who underwent surgery were analyzed. Cognitive impairment was defined as a decrease of Cognitive Assessment Montreal (MoCA)’s score in at least two cognitive domains or any MoCA’s score of less than 26 points at the time of study compared with baseline level. Multiple potential risk factors including methylated status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter, glioma World Health Organization (WHO) grade, residual tumor volume, education, and sex were analyzed. Cox univariate and multivariate regression analysis was used to detect the significant risk factors for cognitive impairment.


At the end of follow-up among the 229 patients, 147 patients (67%) developed cognitive impairment. 82 patients (36%) remained in normal cognitive condition. In multivariate analysis, unmethylated MGMT promoter (hazard ratio [HR], 1.679; 95% confidence interval [CI], 1.212 to 2.326; p=0.002), glioblastoma (HR, 1.550; 95% CI, 1.117 to 2.149; p=0.009), and residual tumor volume > 5.58 cm3 (HR, 1.454; 95% CI, 1.047 to 2.020; p=0.026) were independent risk factors for cognitive impairment.


Methylated status of the MGMT promoter, glioma WHO grade, and residual tumor volume might be risk factors for the cognitive impairment in postoperative patients with HGG.


High-grade glioma (HGG) is the most common primary brain tumor in the adult central nervous system (CNS), the incidence of which is 27% of the primary CNS tumors and 80% of the malignant primary CNS tumors [1]. According to World Health Organization (WHO) classification, glioma is divided into grade I-IV, of which grade I and II for low-grade glioma, grade III and IV for HGG, also known as malignant glioma.
With the progress of surgery, radiotherapy, and chemotherapy, the 2-year survival rate of patients with malignant primary CNS tumors can be increased to 44.1% [1]. With the prolongation of survival, more attention was paid on cognitive dysfunction of patients with HGG and the decline of life quality.
Tumor itself can lead to cognitive dysfunction. Rapid growth of HGG with high intracranial pressure and neurological dysfunction as the main manifestations could conceal the relative occult cognitive dysfunction [2]. But a detailed examination of 139 patients with different brain tumors found cognitive impairment in 126 patients (91%) [3]. This has attracted our attention on the study of cognitive dysfunction which might have been underestimated in current knowledge.
Radiotherapy has been considered to be the main cause of cognitive impairment [4]. But in recent years, radiotherapy was not considered as the main reason since patients only receive a small region of radiation [5]. Most of the prospective studies less than 5 years of follow-up showed that radiotherapy did not lead to a decline in cognitive function, or was not the main cause of cognitive dysfunction [6,7]. Only one prospective study suggested that radiation might have a detrimental effect on cognitive function, but the patients were followed for more than 10 years [8].
Chemotherapy has a negative effect on cognitive function. Temozolomide (TMZ) is a new type of alkylating agent, with outstanding characteristics including small molecule size, lipid solubility, high degree of biological utilization. After entering the CNS and transforming to antitumor bioactive substances, it could generate a synergistic effect with radiotherapy [9,10]. At present, concurrent radiotherapy and chemotherapy is commonly used in HGG. Retrospective studies have shown that older patients may be associated with cognitive impairment [11].
Cognitive Assessment Montreal (MoCA) is a simple, rapid and convenient tool for screening mild cognitive impairment. It has higher sensitivity and more comprehensive coverage compared with the traditional cognitive screening scale, the Mini-Mental-State Examination (MMSE), which has been widely used [12-14]. The latest version of MoCA includes the following areas: short term memory and delayed recall, visual spatial ability, executive ability, attention, computational power, working memory, language and orientation ability. The total score is 30 points, and the required time for completion is about 10 minutes. Cognitive impairment was defined as a decrease of MoCA’s score in at least two cognitive domains [15] or any MoCA’s score of less than 26 points at the time of study compared with baseline level before radiotherapy. For those who received education of less than or equal to 12 years, the MoCA’s score would be deducted for 1 point to correct bias of cultural degree.
Clinical and molecular biological indicators such as glioma location, grading, residual tumor volume, sex, Karnofsky Performance Status (KPS), peritumoral edema, and O6-methylguanine- DNA methyltransferase (MGMT) promoter methylation status might be risk factors for cognitive impairment in postoperative patients with HGG. The aim of this study was to screen for significant risk factors for cognitive impairment in patients with HGG resection.

Materials and Methods

The flowchart of our study is shown in Fig. 1.

1. Patients

HGG patients after surgery were recruited in multiple hospitals. The recruiting time period was from January 2014 to June 2017. Inclusion criteria included: reception of adjuvant radiotherapy and chemotherapy after HGG resection, age > 18 years, signature of informed consent. Exclusion criteria included: inability of reading or answering the questionnaire, KPS < 70, life expectancy < 3 months, other CNS tumors, other diseases that can cause cognitive impairment (brain trauma, stroke), unsuitability for participation for any other reason.

2. Radiotherapy and chemotherapy protocol with TMZ

For patients with newly resected HGG, standard treatment included fractionated external beam radiation therapy with concomitant administration of TMZ followed by up to six cycles of adjuvant TMZ (combined chemotherapy and radiotherapy [CCRT]). The detailed description of radiotherapy and TMZ treatment was referred to National Comprehensive Cancer Network clinical practice guidelines in Oncology: Central Nervous System Cancers (2014.V1) and the reference [16]. HGG could be a histological grade 3 anaplastic glioma (AG) or a grade 4 glioblastoma (GBM). For AG, T2-weighted magnetic resonance imaging (MRI) sequences and the region of contrast enhancement in T1-weighted MRI sequences are considered for the delineation of the gross tumor volume, and an iso-tropic expansion of 15 to 20 mm is recommended for the clinical target volume (CTV). For GBM, the Radiation Therapy Oncology Group favors a two-step technique, with an initial phase (CTV1) including any T2 hyperintensity area (edema) plus a 20 mm margin treated with up to 46 Gy in 23 fractions, followed by a reduction in CTV2 to the contrast enhancement region in T1 with an additional 25 mm margin. A total dose of 60 Gy in 30 fractions is usually delivered for HGG. Based on the fusion of MRI enhanced scan and computed tomography plain scan image, the radiotherapy target area delineation design is performed. Irradiation was delivered to the patients by a 6-MV X-ray linear accelerator. All the patients received conformal external beam radiotherapy administered in a daily dosage of 2 Gy for 5 days per week, achieving a total dose of 60 Gy. All the patients received concurrent TMZ at a dose of 75 mg/m2/day orally. Additionally, adjuvant six cycles of TMZ (150-200 mg/m2 for 5 days) were given in every 28 days.

3. Protocol for evaluating risk factors

Cognitive impairment was defined as a decrease in the score of at least two cognitive domains or MoCA’s score < 26 points compared with baseline (before combined chemotherapy and radiotherapy). For those who received education of less than or equal to 12 years, the MoCA’s score would be deducted for 1 point to correct cultural degree bias. Key evaluations were made at baseline (after surgery and before radiotherapy and chemotherapy) and at 3, 6, 9, 12, 15, and 18 months after the end of radiotherapy. The content of evaluations included MoCA’s score and the analysis of concurrent brain enhanced MRI examination. Follow-up was discontinued at the time of tumor progression. Brain MRI examination was used to assess recurrence or progression diseases.

4. Statistical analysis

The incidence of cognitive impairment at different time points of treatment was calculated using the Kaplan-Meier method. The potential risk factors considered in the analysis were age, KPS, laterality, sex, residual tumor volume, education, MGMT promoter methylation status, and edema. All risk factors except residual tumor volume were included as categorical variables in the model. The cutoff value of the residual tumor volume determined by the receiver operating characteristic (ROC) curve is used as its categorical variable. Univariate Cox proportional hazard models were used to evaluate risk factors of cognitive impairment in postoperative patients with HGG. The p-value of less than 0.05 is considered to be statistically significant. The independent risk factors of the cognitive impairment were screened by multi-variate Cox proportional hazard models. The discrimination ability of the prediction model is indicated by the most commonly used area under the ROC curve (AUC), also known as C-statistics. The larger the AUC, the better the discriminative ability of the predictive model. Generally, AUC < 0.6 indicates that the discrimination degree is low, AUC 0.6-0.75 indicates that the model has a certain distinguishing ability, and AUC > 0.75 implies that the distinguishing ability is better. The Hosmer-Lemefitting test is used to evaluate the calibration ability of the prediction model. All analyses were performed using SPSS ver. 15.0 (SPSS Inc., Chicago, IL).

5. Ethical statement

The research followed the Helsinki declaration (guidelines Helsinki). The study was approved by the Institutional Review Board of Laiwu Central Hospital, Xinwen Mining Group (IRB No. 201401016). All patients signed the informed consent.


Table 1 provides information on the number of patients eligible for analysis at each follow-up timepoint.
Table 2 shows the characteristics of the study population. Among the respondents, 60.5% were WHO grade Ⅳ and 57.2% had methylated MGMT promoter.
Fig. 2 shows the incidence of cognitive impairment at different time points.
At the end of follow-up, 147 patients (64.2%) developed cognitive impairment and 82 patients (35.8%) did not. The median follow-up duration regarding cognitive function was 9.0 months (95% confidence interval [CI], 7.85 to 10.15) and the incidence of cognitive impairment curve is presented in Fig. 2. MoCA scores of baseline (before radiotherapy and chemotherapy), 3, 6, 9, 15, and 18 months were 26.86±1.00, 26.49±2.15, 26.80±1.64, 26.29± 1.85, 26.34±2.92, 26.70±2.13, and 26.31±2.85, respectively. One-way ANOVA analysis for MoCA score showed that there were significant differences between each follow-up timepoint (F=2.33, p=0.03), among which, significant difference was found between the 9 months and baseline group, no differences were found between other groups.
The incidence of cognitive impairment in the cohort (n=229) presented in a survival plot (Fig. 2).
We evaluated the established risk factors (p < 0.1) of cognitive impairment in a Cox multivariate survival analysis. The results are presented in Table 3 and Fig. 3A-C. In multi-variate analysis that included MGMT promoter methylation status, WHO glioma grade, residual tumor volume, education, and sex, we found three independent risk factors for cognitive impairment: positive MGMT promoter methylation (hazard ratio [HR], 1.679; 95% CI, 1.212 to 2.326; p=0.002)(Fig. 3A), GBM (HR, 1.550; 95% CI, 1.117 to 2.149; p=0.009) (Fig. 3B), residual tumor volume > 5.58 cm3 (HR, 1.454; 95% CI, 1.047 to 2.020; p=0.026) (Fig. 3C).
Cognitive impairment curves for the independent predictors presented in Table 3 including MGMT promoter methylation status (Fig. 3A), glioma grade (Fig. 3B), residual tumor volume (Fig. 3C).
We further analyzed the radiotherapy dose (Gy, x±s) delivered to the bilateral hippocampi and the whole brain in cognitive impairment group and no cognitive impairment group. Using t test analysis for independent samples by SPSS statistical software, no significant differences were found for the delivered dose of bilateral hippocampi and the whole brain between the two groups. Accordingly, the delivered dose for bilateral hippocampi and the whole brain was excluded as a confounding factor in the current study (Table 4).
The discrimination ability of the risk prediction model was measured using C-statistics and was found to be 0.671 (95% CI, 0.600 to 0.742). Figs. 4 and 5 show the discrimination and calibration plots for the cognitive impairment risk prediction model. The Hosmer-Lemeshow type chi-square value was 4.085 (p=0.665).


In recent years, CCRT followed by adjuvant TMZ is the standard treatment for postoperative HGG patients. The regimen had more favorable survival rates than those who did not undergo this treatment and tolerable toxicity [17,18]. The application of molecular biology for precision medicine can accurately reflect the molecular biological characteristics and clinical treatment effects and prognosis of glioma [19,20]. Multiple molecular biology indicators and gene factors of glioma were reported to be related to neurocognitive function [21]. For example, the IDH1 gene mutation was considered to contribute to cognitive impairment in malignant astrocytoma [22].
The current study prospectively examined risk factors for cognitive impairment in postoperative patients with HGG after radiotherapy. We firstly found that MGMT promoter methylation status was an independent risk factor. MGMT is a repair enzyme that removes promutagenic O6-methylguanine adducts in DNA. The methylation of MGMT promoter may affect MGMT expression and activity. The DNA repair protein MGMT is known to play a role in affecting sensitivity to TMZ [23] and is significantly associated with survival [24] and is an independent risk factor for prognosis [25]. Negative MGMT promoter methylation status as higher risk of cognitive impairment than positive status. Considering the large number oncogenic or promutagenic molecules that play a role in glioma development and progression, more potential risk factors for cognitive impairment in postoperative patients with HGG need to be further explored in the context of precision medicine [26].
Another independent risk factor for cognitive impairment is WHO histological grade of glioma. Previous findings demonstrated different levels of impairment in the executive and memory domains inpatients with low- and high-grade glioma [27]. Compared with patients with grade II or III left temporal lobe glioma, patients with grade IV glioma exhibit greater difficulty with verbal learning, processing speed, executive functioning, and language [28]. The study for longterm effects of radiotherapy on cognitive function in adult low-grade glioma patients reported that the group receiving postoperative irradiation performed significantly worse than the group without radiotherapy. This difference was not attributed to histologic diagnosis; location, extent of removal, or progression of the tumor [29]. Our study found that grade IV glioma has a higher risk of cognitive impairment than that of grade III after CCRT.
Glioma residual tumor volume is also an independent risk factor for cognitive impairment in postoperative patients with HGG after radiotherapy. The risk of cognitive impairment in patients with HGG volume greater than 5.58 cm3 after CCRT is greater than volume less than 5.58 cm3. Our findings are consistent with the previous study showing that tumor itself significantly affects cognitive functions, mainly due to the mass effect and higher grading [30].
Although this study provides important findings about risk factor on cognitive impairment of the postoperative patients with HGG after radiotherapy, limitations must be acknowledged. Firstly, we have only studied one molecular biological indicator, MGMT. Under the precise medical treatment model, more molecular biology and genetic indicators for the risk of cognitive impairment need to be further explored. Secondly, multicenters can affect the following issues which might cause unavoidable biases: (1) the TMZ manufacturer and the MGMT promoter methylation molecular biology testing company was not specified; (2) imaging examination may be influenced by the subjective judgment of the physician; (3) radiotherapy effects may be affected by the type of equipment and physician's skills.
Detailed classification of specific location of tumor did play a role in the study of cognitive impairment. Cox univariate analysis showed significant differences between different locations of tumors, among which tumors at temporal lobe manifested the most significant effect on cognitive impairment. Cox multivariable analysis showed no significant differences at different locations of tumor (Table 3).
In summary, cognitive impairment in postoperative patients with HGG after radiotherapy and chemotherapy is a significant clinical issue. MGMT promoter methylation, glioma WHO tumor grade and residual tumor volume are independent risk factors for cognitive impairment. We suggest patients at high risk should be closely monitored and provided with recommendations for appropriate interventions, individualized treatment and optimized patient management. Both clinical and genetic factors might simultaneously be associated with cognitive impairment developed during radiotherapy plus TMZ. Future studies require multi-center cooperation. More patients and more biological and genetic indicators in larger prospective studies should be included in the construction of more accurate and more effective risk prediction models.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Fig. 1.
Flowchart of the study. HGG, high-grade glioma; MoCA, Cognitive Assessment Montreal; MRI, magnetic resonance imaging.
Fig. 2.
The incidence of cognitive impairment in the cohort (n=229) presented in a survival plot.
Fig. 3.
Cognitive impairment curves for the independent predictors. (A) O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status of high-grade glioma (HGG). (B) HGG. (C) Residual tumor volume of HGG.
Fig. 4.
Discrimination for risk prediction model of cognitive impairment by receiver operating characteristic curve.
Fig. 5.
Calibration of cognitive impairment risk model.
Table 1.
Characteristics of the study population
Time point Cognitive impairment Disease progression Eligible patients
1 (before treatment) 0 - 335
2 (3 mo) 20 12 303
3 (6 mo) 15 16 272
4 (9 mo) 56 24 192
5 (12 mo) 27 26 139
6 (15 mo) 10 17 112
7 (18 mo) 19 11 82
Total 147 106
Table 2.
Demographic, clinical, and molecular characteristics of patients.
Clinical characteristic No. of patients (%)
 Male 135 (59.0)
 Female 94 (41.0)
Age (yr)
 < 60 118 (51.5)
 ≥ 60 111 (48.5)
 Left 124 (54.1)
 Right 105 (45.9)
Mean residual tumor volumea) (cm3)
 ≤ 5.58 92 (40.2)
 > 5.58 137 (59.8)
WHO grade
 Anaplastic astrocytoma 88 (38.4)
 Glioblastoma 141 (60.5)
KPS (%)
 70-80 78 (34.1)
 80-90 102 (44.5)
 90-100 49 (21.4)
 Yes 104 (45.4)
 No 125 (54.6)
Education (yr)
 < 12 127 (55.5)
 ≥ 12 102 (44.5)
MGMT promoter methylation statusb)
 Positive 131 (57.2)
 Negative 98 (42.8)
 Frontal lobe 34 (14.8)
 Temporal lobe 125 (54.6)
 Parietal lobe 26 (11.4)
 Occipital lobe 44 (19.2)

WHO, World Health Organization; KPS, Karnofsky Performance Status; MGMT, O6-methylguanine-DNA methyltransferase; ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval.

a) Residual tumor volume: determined by T1 enhanced magnetic resonance imaging. The ROC analysis showed that the optimal cutoff value for glioma volume was 5.58 cm3 (AUC, 0.778; 95% CI, 0.714-0.843; sensitivity, 0.823; specificity, 0.645; Yoden index, 0.469),

b) MGMT promoter methylation status was determined by pyrosequencing using cutoff value of > 5% positivity of methylated alleles.

Table 3.
Results of Cox univariate and multivariate regression analysis
Univariate analysis
Multivariate analysis
95% CI for Multivariate HR
HR p-value HR p-value
Sex 0.730 0.067 1.212 0.272 0.86-1.709
Edema 0.965 0.831 - - -
Education 0.742 0.080 1.205 0.276 0.862-1.686
KPS 0.948 0.644 - - -
Age 0.762 0.104 - - -
MGMT 1.657 0.002 1.813 0.001 1.297-2.535
Laterality 0.807 0.201 - - -
Volume 1.489 0.017 1.454 0.021 1.06-2.044
Grade 1.501 0.015 1.449 0.029 1.039-2.02
Lobe 1.714 0.043 1.433 0.271 0.755-2.718

HR, hazard ratio; CI, confidence intervla; KPS, Karnofsky Performance Status; MGMT, O6-methylguanine-DNA methyltransferase.

Table 4.
Delivered dose to the bilateral hippocampi and the whole brain
Group No. Maximum dose for BH (Gy) Mean dose for BH (Gy) Maximum dose for WB (Gy) Mean dose for WB (Gy)
CI 147 39.28±8.14 31.85±9.13 57.14±3.79 30.43±3.65
NCI 82 41.00±8.61 33.62±9.02 58.01±4.33 31.20±3.97
t –1.49 –1.53 –1.51 –1.45
p-value 0.139 0.127 0.133 0.149

BH, bilateral hippocampi; WB, whole brain; CI, cognitive impairment; NCI, no cognitive impairment.


1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17 Suppl 4:iv1–62.
crossref pmid
2. Klein M, Taphoorn MJ, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, et al. Neurobehavioral status and healthrelated quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001;19:4037–47.
3. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47:324–33.
crossref pmid pdf
4. Sarkissian V. The sequelae of cranial irradiation on human cognition. Neurosci Lett. 2005;382:118–23.
crossref pmid
5. Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology. 2002;59:40–8.
crossref pmid
6. Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys. 2010;77:662–9.
crossref pmid
7. Laack NN, Brown PD, Ivnik RJ, Furth AF, Ballman KV, Hammack JE, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys. 2005;63:1175–83.
crossref pmid
8. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatmentrelated factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361–8.
crossref pmid
9. Verger E, Gil M, Yaya R, Vinolas N, Villa S, Pujol T, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005;61:185–91.
crossref pmid
10. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20:3644–50.
crossref pmid
11. Saito K, Mukasa A, Narita Y, Tabei Y, Shinoura N, Shibui S, et al. Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. Neurol Med Chir (Tokyo). 2014;54:272–9.
crossref pmid
12. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.
crossref pmid
13. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007;52:329–32.
crossref pmid
14. Wang Q, Qi F, Song X, Di J, Zhang L, Zhou Y, et al. A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy. J Cancer Res Ther. 2018;14(Suppl):S1048–51.
15. Durand T, Jacob S, Lebouil L, Douzane H, Lestaevel P, Rahimian A, et al. EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients. BMC Neurol. 2015;15:261.
crossref pmid pmc
16. Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches. Chin J Cancer. 2014;33:16–24.
crossref pmid pmc
17. Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, et al. Concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide for newly diagnosed glioblastoma patients: a retrospective multicenter observation study in Korea. Cancer Res Treat. 2017;49:193–203.
crossref pmid pdf
18. Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, et al. Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme. Cancer. 2016;122:2364–70.
crossref pmid
19. Woo PY, Ho JM, Tse TP, Lam SW, Mak CH, Chan DT, et al. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: a multicenter cohort study. J Clin Neurosci. 2019;63:134–41.
crossref pmid
20. Yang K, Jung SW, Shin H, Lim DH, Lee JI, Kong DS, et al. Cancer genetic markers according to radiotherapeutic response in patients with primary glioblastoma: radiogenomic approach for precision medicine. Radiother Oncol. 2019;131:66–74.
crossref pmid
21. Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol. 2016;18:1656–63.
crossref pmid pmc pdf
22. Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol. 2017;131:565–74.
crossref pmid pdf
23. Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, et al. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. J Neurooncol. 2013;114:135–40.
crossref pmid pdf
24. Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol. 2018;233:378–86.
crossref pmid
25. Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac V, et al. Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. Radiol Oncol. 2016;50:394–401.
crossref pmid pmc pdf
26. Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, et al. Genetic modulation of neurocognitive function in glioma patients. Clin Cancer Res. 2015;21:3340–6.
crossref pmid pmc
27. Miotto EC, Junior AS, Silva CC, Cabrera HN, Machado MA, Benute GR, et al. Cognitive impairments in patients with low grade gliomas and high grade gliomas. Arq Neuropsiquiatr. 2011;69:596–601.
crossref pmid pdf
28. Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol. 2015;17:580–7.
crossref pmid pdf
29. Surma-aho O, Niemela M, Vilkki J, Kouri M, Brander A, Salonen O, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56:1285–90.
crossref pmid
30. Talacchi A, Santini B, Savazzi S, Gerosa M. Cognitive effects of tumour and surgical treatment in glioma patients. J Neurooncol. 2011;103:541–9.
crossref pmid pdf
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community